secwatch.observer — SEC 8-K summary
======================================

Issuer:     TherapeuticsMD, Inc. (TXMD)
CIK:        0000025743
Form:       8-K
Filed at:   2023-01-18T23:59:59+00:00
Accession:  0001193125-23-010258
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

TherapeuticsMD terminates employment agreement of CFO Michael Donegan; remains as consulting CFO
--------------------------------------------------------------------------------

- CFO Michael Donegan's employment agreement terminated without 'Good Cause' effective Dec 30, 2022.
- Separation benefits: 12-month base salary, 2022 target bonus, 24 months COBRA, full equity vesting.
- Eligible for $135k in performance bonuses under 2022 ERB-Plan, including $67.5k for transition assistance.
- Donegan continues as Principal Financial Officer and Principal Accounting Officer in consulting capacity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/25743/000119312523010258/0001193125-23-010258-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/25743/000119312523010258/d399403d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-010258

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer